Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

@article{Petrylak2004DocetaxelAE,
  title={Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.},
  author={Daniel P. Petrylak and Catherine M. Tangen and Maha H.A. Hussain and Primo N. Jr. Lara and Jeffrey Alun Jones and Mary-Ellen Taplin and Patrick A. Burch and Donna L. Berry and Carol M. Moinpour and Manish Kohli and Mitchell C. Benson and Eric J. Small and Derek Raghavan and E. David Crawford},
  journal={The New England journal of medicine},
  year={2004},
  volume={351 15},
  pages={
          1513-20
        }
}
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent prostate cancer. We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer. METHODS We randomly assigned 770 men to one of two treatments, each given in 21-day cycles: 280 mg of estramustine three times daily on days 1 through 5, 60 mg of docetaxel per square meter of body-surface area on… 

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

TLDR
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.

Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.

TLDR
Responses were promising and toxicity was tolerable, suggest that docetaxel-based chemotherapy is going to play an important role as a regimen for patients with HRPC, and support the findings of recently published studies.

Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.

  • A. FontA. Murias R. Rosell
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
TLDR
Mitoxantrone/prednisone followed by docetaxel/estramustine is a well-tolerated and active regimen in HRPC and can be used to integrate novel, more active regimens.

Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

TLDR
The low-dose combination of docetaxel, estramustine and dexamethasone is active and tolerable with beneficial effects on serum PSA levels, performance status, anemia and bone pain in Japanese patients with CRPC.

Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

TLDR
This combination of zoledronic acid, docetaxel and estramustine seemed effective; however toxic deaths especially from venous thrombosis counterbalanced the advantage of this regimen.

Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer

TLDR
The combination of docetaxel, estramustine and prednisolone was effective in Japanese patients with CRPC; however, this combination therapy should be carefully indicated to elderly and/or poor performance status patients due to its toxicity.

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

  • J. MachielsF. Mazzeo J. Kerger
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
The addition of estramustine to weekly D does not provide any clinically relevant advantage, and both regimens are well tolerated, although the toxicity profile favors D without estramUSTine.

Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.

TLDR
The profile of activity of thalidomide/paclitaxel/estramustine in taxane-refractory AIPC warrants further investigation.

[Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].

TLDR
Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy is an effective and well tolerated treatment for Japanese HRPC patients.

Docetaxel in hormone-refractory metastatic prostate cancer.

TLDR
Compared with mitoxantrone plus prednisone, docetaxel plusprednisone improved prostate specific antigen response rate, pain and health-related quality of life, and docetAXel plus estramustine increased progression-free survival.
...

References

SHOWING 1-10 OF 22 REFERENCES

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

TLDR
When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

TLDR
The recommended phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/ m2 in EPT patients, which is active in men with androgen-independent prostate cancer.

Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.

TLDR
Early studies indicate that the combination of estramustine and docetaxel has activity in this population of patients, demonstrating greater than a 50% decline in prostate-specific antigen.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  • I. TannockD. Osoba K. Murphy
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
Chemotherapy with mitoxantrone and prednisone provides palliation for some patients with symptomatic hormone-resistant prostate cancer and most responding patients had an improvement in quality-of-life scales and a decrease in serum prostate-specific antigen (PSA) level.

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  • D. SavareseS. Halabi N. Vogelzang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
This therapy is efficacious and moderately well tolerated in HRPC and should be compared in a phase III trial with mitoxantrone and prednisone.

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.

  • G. HudesL. Einhorn B. Roth
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Although overall survival was not significantly greater for the combination, EM-V was superior to V for time to progression and PSA improvement, which encourage further study of estramustine-based antimicrotubule drug combinations in HRPC.

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

TLDR
Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy, and a survival benefit appears achievable from these early studies.

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

TLDR
MP provides useful palliation in symptomatic men with HRPC and clodronate does not increase the rate of palliative response or overall quality of life.